Hematologic malignancies and myeloproliferative neoplasms
Italfarmaco S.p.A. supports clinical research in polycythemia vera and broader chronic myeloproliferative neoplasms, with particular attention to JAK2V617F-positive disease. The funded studies focus on treatment activity and longer-term clinical management in this blood cancer setting.
- Polycythemia vera
- Chronic myeloproliferative neoplasm
- JAK2V617F-positive disease
These programs reflect sustained interest in therapies for myeloproliferative disorders and related hematology indications.
Duchenne muscular dystrophy and neuromuscular disease
The sponsor has a strong clinical research presence in Duchenne Muscular Dystrophy, including studies in younger children and in non-ambulant patients. Its trials address both disease progression and ongoing treatment needs across the neuromuscular spectrum.
- Duchenne Muscular Dystrophy
- Non-ambulant DMD
- Muscle decline
Research activity in this area also includes long-term observation of safety, tolerability, and treatment continuity in neuromuscular disorders.
Advanced solid tumors and oncology
Italfarmaco also funds studies in advanced solid tumors, extending its clinical portfolio into oncology. These investigations are centered on therapeutic activity in patients with advanced malignant disease.
- Advanced solid tumors
- Oncology
- Anticancer therapy
This area shows the sponsor’s involvement in treatment development for difficult-to-manage cancer populations.
Hepatic impairment and liver function
The sponsor supports clinical evaluation in participants with mild hepatic impairment, moderate hepatic impairment, and normal hepatic function. These studies are relevant to understanding how therapies behave in the setting of altered liver function.
- Mild hepatic impairment
- Moderate hepatic impairment
- Normal hepatic function
This research area is linked to clinical assessment of treatment use in patients with varying degrees of hepatic disease.
Women’s health and contraception
Italfarmaco funds research in female contraception, with attention to menstrual cycle control and treatment acceptability in women. This adds a women’s health dimension to its clinical trial portfolio.
- Female contraception
- Menstrual bleeding
- Hormonal contraception
The sponsor’s interest in this domain covers routine reproductive health and the clinical performance of oral contraceptive options.
